Compare · CARL vs SYK
CARL vs SYK
Side-by-side comparison of Carlsmed Inc. (CARL) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CARL and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 295.3x CARL ($380.9M).
- Over the past year, CARL is down 6.0% and SYK is down 22.8% - CARL leads by 16.8 points.
- CARL has been more active in the news (12 items in the past 4 weeks vs 7 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 6 for CARL).
- Company
- Carlsmed Inc.
- Stryker Corporation
- Price
- $13.44-4.21%
- $294.69+0.46%
- Market cap
- $380.9M
- $112.48B
- 1M return
- -12.50%
- +5.16%
- 1Y return
- -6.01%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 12
- 7
- Recent ratings
- 6
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CARL
- SEC Form 144 filed by Carlsmed Inc.
- Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
- SEC Form 4 filed by Carlsmed Inc.
- Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Operating Officer Bertolini Jeffrey sold $3,400 worth of shares (243 units at $13.99) as part of a pre-agreed trading plan and exercised 243 shares at a strike of $2.23 (SEC Form 4)
- SEC Form S-8 filed by Carlsmed Inc.
- Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
- New insider Kamocsay Jennifer claimed ownership of 56,222 shares (SEC Form 3)
- CFO, Treasurer Heppenstall Richard was granted 89,286 shares (SEC Form 4)
- SEC Form 3 filed by new insider Heppenstall Richard
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)